Inhalation & Nasal Spray Generic Drugs Market By Drug Class (Corticosteroids, Bronchodilators, Antihistamines, Decongestant Sprays, Others), By Application (Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Allergic Rhinitis, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0884 Report Format: PDF + Excel

Inhalation & Nasal Spray Generic Drugs Market Overview

Inhalation & Nasal Spray Generic Drugs Market size is estimated to reach $15.6 billion by 2027, growing at a CAGR of 4.8% during the forecast period 2022-2027. Inhalation and nasal spray generic medications typically involve a delivery device like a nasal spray. An inhaler (also termed a puffer, pump, or allergy spray) is utilized for transferring medicines into the lungs. There is an extensive assortment of inhalers, and are typically utilized to treat many medical conditions, including asthma and chronic obstructive pulmonary disease (COPD). Nasal sprays are utilized to transfer medicines locally in the nasal cavities or systemically. They are applied locally for conditions like nasal congestion and allergic rhinitis. Intranasal corticosteroids are accepted as a safe and effective first-line therapy for allergic rhinitis. Intranasal corticosteroids are natural hormones discovered in the body that decrease swelling of the lining of the nose. When Budesonide Nasal Spray is sprayed into the nose, it assists in decreasing the nasal symptoms of allergic rhinitis (inflammation of the lining of the nose), like stuffy nose, runny nose, itching, and sneezing. Tiotropium Inhalation Spray under the brand name: Spiriva Respimat comes under the drug class: Anticholinergic bronchodilators which obstruct the parasympathetic nerve reflexes that bring about the airways to inhibit, thereby permitting the air passages to stay open. Anticholinergic bronchodilators are utilized more to treat a chronic obstructive pulmonary disease than to treat asthma. Nasal steroids (also termed nasal corticosteroids) are medications including corticosteroids like beclomethasone, budesonide, fluticasone, or triamcinolone in a preparation planned for nasal application.

The exorbitant healthcare costs in the developed countries are propelling the increasing patient pool toward generic medications and this is set to drive the Inhalation & Nasal Spray Generic Drugs Market. The expanding population of the elderly and the increasing pervasiveness of asthma, chronic obstructive pulmonary disorder (COPD), and other respiratory ailments requiring the application of inhaled corticosteroids are set to propel the growth of the Inhalation & Nasal Spray Generic Drugs Market during the forecast period 2022-2027. This represents the Inhalation & Nasal Spray Generic Drugs Industry Outlook.

Report Coverage

The report: Inhalation & Nasal Spray Generic Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Inhalation & Nasal Spray Generic Drugs Market.

By Drug Class: Corticosteroids, Bronchodilators, Antihistamines, Decongestant Sprays, Others.
By Application: Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Allergic Rhinitis, Others.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Inhalation & Nasal Spray Generic Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring count of Americans residing with asthma requiring the application of inhaled corticosteroids in the U.S. in the North American region.
  • Inhalation & Nasal Spray Generic Drugs Market growth are being driven by the increasing predominance of asthma and Chronic Obstructive Pulmonary Disorder (COPD) requiring the application of inhaled corticosteroids and the reduced cost of generic medications. However, with the accessibility of surging count of reduced cost generic inhalation and nasal spray medications across the world, different regulatory bodies have authorized tight norms to target quality and this is one of the major factors hampering the growth of Inhalation & Nasal Spray Generic Drugs Market. 
  • Inhalation & Nasal Spray Generic Drugs Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Inhalation & Nasal Spray Generic Drugs Market report. 

Inhalation & Nasal Spray Generic Drugs Market: Market Share (%) by Region, 2021

Inhalation & Nasal Spray Generic Drugs Market

For more details on this report - Request for Sample

Inhalation & Nasal Spray Generic Drugs Market Segment Analysis – By Drug Class

The Inhalation & Nasal Spray Generic Drugs Market based on drug class can be further segmented into Corticosteroids, Bronchodilators, Antihistamines, Decongestant Sprays, and Others. The Corticosteroids Segment held the largest market share in 2021. This growth is owing to the surging application of corticosteroids for the treatment of asthma and chronic obstructive respiratory disorder (COPD). The beneficial impacts of inhaled corticosteroids in asthma-like the decreased severity of symptoms, enhanced pulmonary function, restricted bronchial hyperresponsiveness (BHR), avoidance of aggravations, and likely avoidance of airway wall remodeling are further propelling the growth of the Corticosteroids segment.

Furthermore, the Bronchodilators segment is estimated to grow with the fastest CAGR of 5.6% during the forecast period 2022-2027 owing to the soaring application of bronchodilators to enhance symptoms and lung function in asthma and chronic obstructive pulmonary disorder (COPD).

Inhalation & Nasal Spray Generic Drugs Market Segment Analysis – By Application:

The Inhalation & Nasal Spray Generic Drugs Market based on the application can be further segmented into Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Allergic Rhinitis, and Others. The Asthma Segment held the largest market share in 2021. This growth is owing to the increasing predominance of asthma among children internationally. Corticosteroids are medicines utilized to treat asthma and certain allergic conditions like skin allergy. The surging urbanization and exposure to a series of environmental allergens and irritants are further propelling the growth of this segment.

Furthermore, the Chronic Obstructive Pulmonary Disorder (COPD) segment is estimated to grow with the fastest CAGR of 6.2% during the forecast period 2022-2027 owing to the increasing predominance of chronic obstructive pulmonary disorder (COPD) requiring treatment options like stopping smoking, inhaling corticosteroids as prescribed by physicians, and pulmonary rehabilitation.

Inhalation & Nasal Spray Generic Drugs Market Segment Analysis – By Geography:

The Inhalation & Nasal Spray Generic Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Inhalation & Nasal Spray Generic Drugs Market) held the largest share with 36% of the overall market in 2021. The growth of this region is owing to the soaring level of patient security and care protocols kept up in the region by way of the imposition of binding government regulations in the North American region. Inhaled corticosteroids are the principal treatment to bring down inflammation and avert flare-ups in asthma. The surging prevalence of asthma and chronic obstructive pulmonary disorder (COPD) and the well-entrenched healthcare infrastructure are further propelling the growth of the Inhalation & Nasal Spray Generic Drugs Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the proliferating patient pool enduring asthma and chronic obstructive pulmonary disorder (COPD) requiring the application of corticosteroids and bronchodilators in the Asia-Pacific region. The accelerated evolution of the healthcare industry together with the greatest population density in the world is further fuelling the progress of the Inhalation & Nasal Spray Generic Drugs Market in the Asia-Pacific region.

Inhalation & Nasal Spray Generic Drugs Market Drivers

Surging Applications Of Corticosteroids And Bronchodilators Are Projected To Drive The Growth Of Inhalation & Nasal Spray Generic Drugs Market:

Long-acting salmeterol and formoterol, served only twice every day, can reduce symptoms of asthma day and night time. Inhaled corticosteroids are the principal treatment to decrease inflammation and avoid flare-ups in asthma. According to Food and Agriculture Organization, in 2019, 40.4% of adults age 18 and older who had asthma reported having one or more asthma attacks in the past year. However, certain people may also gain from consuming bronchodilators to keep the airways open and to improve the impacts of corticosteroids. Long-acting bronchodilators need to never be consumed without corticosteroids. In Chronic Obstructive Pulmonary Disorder (COPD), initial treatment is with short- or long-acting bronchodilators, with corticosteroids included in certain serious cases. Treatment with corticosteroids and bronchodilators may need the application of segregated inhalers, however, increasingly these medicines are offered together in single inhalers. The surging applications of corticosteroids and bronchodilators are therefore fuelling the growth of the Inhalation & Nasal Spray Generic Drugs Market during the forecast period 2022-2027.

Increasing Pervasiveness of Allergic Rhinitis Is Expected To Boost The Demand For Inhalation & Nasal Spray Generic Drugs:

As per the American Academy Of Allergy, Asthma & Immunology (AAAAI), between 10% and 30% of the global population endures allergic rhinitis. Allergic rhinitis, more typically recognized as hay fever, is assisted by symptoms like sneezing and itchy, swollen, or watery eyes, and a stuffy or runny nose. In the U.S., white children are more probable to endure allergic rhinitis (10%) than black children (7%). Allergic rhinitis is a typical and chronic immunoglobulin E–mediated respiratory sickness that can influence the quality of life and productivity, and aggravate additional conditions like asthma. Treatment needs to be based on the age of the patient and the severity of symptoms. Patients need to be informed regarding their condition and advised to prevent recognized allergens. Intranasal corticosteroids are the most efficient treatment and need to be the earliest-line therapy for determining symptoms influencing the quality of life. The more serious ailment that does not respond to intranasal corticosteroids needs to be treated with second-line therapies, inclusive of antihistamines, decongestants, cromolyn, leukotriene receptor antagonists, and nonpharmacologic therapies like nasal irrigation. Subcutaneous or sublingual immunotherapy needs to be examined if typical treatments do not sufficiently curb symptoms in patients with allergic asthma. The increasing pervasiveness of Allergic Rhinitis is therefore driving the growth of the Inhalation & Nasal Spray Generic Drugs Market during the forecast period 2022-2027.

Inhalation & Nasal Spray Generic Drugs Market Challenges

Challenges Of Inhalation Spray Medications Are Hampering The Growth Of The Inhalation & Nasal Spray Generic Drugs Market:

As per WebMD, 40% of children and 30% of mature grown-ups possess allergies in the U.S. As documented by the U.S. Food And Drug Administration (FDA), the possible extensive assortment of inhalation spray medication product designs with rare properties will offer an array of development challenges. Disregarding the design, the most critical attributes are the reproducibility of the dose, the spray plume, and the particle/droplet size distribution, owing to these parameters influencing the delivery of the medication substance to the planned biological target. Keeping up the reproducibility of these parameters by way of the expiration dating period and guaranteeing the sterility of the content and the functionality of the device (for example, spray mechanism, electronic features, sensors) by way of its lifetime under patient-use conditions will possibly offer the most formidable challenges. Thus, alterations in constituents of the medication product or alterations in the maker or making procedure that can influence these parameters needs to be cautiously measured for their impact on the security, clinical effectiveness, and stability of the product. If such alterations are made subsequent to the preparation of the batches utilized in crucial clinical, bioequivalence, or primary stability investigations, sufficient supportive comparative data needs to be offered to display equivalency in terms of security, clinical effectiveness, and stability of the product. These issues are thus hampering the growth of the Inhalation & Nasal Spray Generic Drugs Market.

Inhalation & Nasal Spray Generic Drugs Industry Outlook:

Technological innovations and mergers and acquisitions are key strategies adopted by players in the Inhalation & Nasal Spray Generic Drugs Market. Key companies of this market are:

  1. Teva Pharmaceuticals
  2. Mylan N.V. (Viatris)
  3. Akorn, Inc.
  4. Cipla Ltd.
  5. Sandoz Pharmaceutical Company
  6. Apotex Inc.
  7. Beximco Pharma
  8. Hikma Pharmaceuticals plc
  9. Ranbaxy (Sun Pharma)
  10. Perrigo Company plc

Recent Developments

  • In August 2021, Hikma Pharmaceuticals PLC (Hikma), declared the introduction of KLOXXADOTM (naloxone HCl) nasal spray 8mg in the U.S. KLOXXADOTM was certified by the U.S. Food and Drug Administration (FDA) in April 2021 for the emergency treatment of recognized or suspected opioid overdose, as personified by respiratory and/or central nervous system depression, for mature grown-up and pediatric patients. KLOXXADOTM includes twice as much naloxone per spray as Narcan® Nasal Spray medication in a ready-to-use nasal spray to reverse the impacts of opioid overdose, offering a significant novel treatment alternative in attending to the opioid outbreak.
  • In August 2019, Hikma Pharmaceuticals settled to gain two nasal sprays and unit-dose nasal spray manufacturing assets from Insys Therapeutics, the firm pronounced. In June 2019, Insys announced bankruptcy and pronounced that it would market all of its assets. Hikma did not announce how much it paid for the naloxone and epinephrine nasal sprays.
  • In August 2019, Perrigo Company plc declared that it has established its Hatch-Waxman litigation connecting to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc. The terms of the settlement are classified. Annual market sales for the 12-months ending June 2019 were $90 million as determined by IQVIA™.

Related Reports-

Inhalation Toxicology Testing Services Market – Forecast (2022 - 2027)
Report Code: HCR 1429

Generic Drugs Market – Forecast (2022 - 2027)
Report Code: HCR 0217

Branded Generics Market – Forecast (2022 - 2027)
Report Code: HCR 0255 

For more Lifesciences and Healthcare related reports, please click here

1. Inhalation & Nasal Spray Generic Drugs Market Overview
    1.1 Definitions & Scope
2. Inhalation & Nasal Spray Generic Drugs Market - Executive Summary
3. Inhalation & Nasal Spray Generic Drugs Market – Market L&scape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Inhalation & Nasal Spray Generic Drugs Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital & Funding Scenario
5. Inhalation & Nasal Spray Generic Drugs Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business & Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Inhalation & Nasal Spray Generic Drugs Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Inhalation & Nasal Spray Generic Drugs Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Inhalation & Nasal Spray Generic Drugs Market – By Drug Class (Market Size –$Million/$Billion) 
    8.1 Corticosteroids
    8.2 Bronchodilators
    8.3 Antihistamines
    8.4 Decongestant Sprays
    8.5 Others
9. Inhalation & Nasal Spray Generic Drugs Market - By Application (Market Size –$Million/$Billion) 
    9.1 Asthma
    9.2 Chronic Obstructive Pulmonary Disorder (COPD)
    9.3 Allergic Rhinitis
    9.4 Others
10. Inhalation & Nasal Spray Generic Drugs Market - By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zeal&
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 Middle East
        10.5.2 Africa
11. Inhalation & Nasal Spray Generic Drugs Market - Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs & partnerships
12. Inhalation & Nasal Spray Generic Drugs Market – Industry Competition L&scape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Inhalation & Nasal Spray Generic Drugs Market – Key Company List by Country Premium (Premium)
14. Inhalation & Nasal Spray Generic Drugs Market - Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"